Summaries by Inventor Guruswami, Sundaram

Design and Development of Organomedicinals for Imaging and Treatment of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (FTD)
Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-016665

— Background Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…

PET tracers for detection of early stage Alzheimer’s disease
Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-013525

— Technology Description Researchers at Washington University in St. Louis have developed PET radiotracers to image amyloid beta (A-beta) at early stages of Alzheimer’s Disease (AD). For AD treatment to be effective, it may have to be administered during the preclinical stage. As such, there i…

Design and Development of Organomedicinals for Imaging and Treatment of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (FTD)
Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-016665

— Background Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…

Nanomaterials for Imaging and Treatment of Amyloidosis
Bieschke, Jan ; Guruswami, Sundaram ; Liu, Yongjian ; Sharma, Vijay
T-017876

— Background 8 million people per year are diagnosed with light-chain (AL) amyloidosis, a progressive disease than can quickly affect the kidney, heart, and nervous system if left untreated. The current method of diagnosis involves histological confirmation via biopsies of bone marrow, fat, and organ…

Nanomaterials for Imaging and Treatment of Amyloidosis
Bieschke, Jan ; Guruswami, Sundaram ; Liu, Yongjian ; Sharma, Vijay
T-017876

— Background 8 million people per year are diagnosed with light-chain (AL) amyloidosis, a progressive disease than can quickly affect the kidney, heart, and nervous system if left untreated. The current method of diagnosis involves histological confirmation via biopsies of bone marrow, fat, and organ…

 

Create a Collection
Creating...